L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia

Summary

Alterations in haemostasis are frequently observed in children with acute lymphoblastic leukemia (ALL). It was the objective of this study to analyse age-related disturbances in coagulation and fibrinolysis parameters during the induction phase of the anti-leukemic treatment. Sixty-four children were classified by age into three groups (1–5, 6–10, 11–16 years), and studied during induction treatment of ALL including four weeks of dexamethasone, followed by two weeks tapering of dexamethasone during which 6,000 IU/m² native L-Asparaginase (total 4 doses) was administered intravenously twice weekly. Blood samples were collected immediately before each L-Asparaginase infusion to analyze procoagulant (fibrinogen, factor [F] II, FV, FVII, F IX, F X) and anticoagulant factors (antithrombin [AT], protein C, protein S), parameters of thrombin generation (F1+2, TAT) and fibrinolysis (α2-antiplasmin, plasminogen, PA P , D-dimer). Children were in a hypercoagulable state after four weeks of dexamethasone due to upregulation of coagulation parameters. Upregulation was highest in the two youngest age groups. During L-Asparaginase treatment the 11– to 16-year- olds showed lower values in procoagulant and, even more, in anticoagulant factor levels compared to the younger children. Activation markers of thrombin generation and fibrinolysis did not change over time during the study period. Decreased synthesis of α2-antiplasmin and plasminogen during L-Asparaginase treatment resulted in less potential of clot lysis by plasmin in children older than 11 years of age. In conclusion, a more severe decline of anticoagulant and fibrinolytic parameters in children between 11 and 16 years of age underline that these children are at higher risk of thrombosis during ALL induction treatment.

Keywords

ALL - developmental haemostasis - L-Asparaginase

• References

• 1 Athale UH, Chan AKC. Thrombosis in children with acute lymphoblastic leukemia Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res 2003; 111: 199-212.
• 2 Asselin BL. The three aspraginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol 1999; 457: 621-629.
• 3 Nowak-Gottl U, Ahlke E, Klosel K. et al. Changes in coagulation and fibrinolysis in childhood acute lymphoblastic leukaemia re-induction therapy using three different asparaginase preparations. Eur J Pediatr 1997; 156: 848-850.
• 4 Nowak-Gottl U, Werber G, Ziemann D. et al. Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL. Haematologica 1996; 81: 127-131.
• 5 Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet 2005; 44: 367-393.
• 6 Appel IM, van Kessel-Bakvis C, Stigter R. et al. Influence of two different regimens of concomittant treatment with asparaginase and dexamethasone on hemostasis in childhood acute lymphoblastic leukemia. Leukemia 2007; 21: 2377-2380.
• 7 Sartori TM, Maurizio PG, Sara P. et al. Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi. J Heart Lung Transplatation 1999; 08: 693-700.
• 8 Andrew M, Vegh P, Johnston M. et al. Maturation of the hemostatic system during childhood. Blood 1992; 80: 1998-2005.
• 9 Monagle P, Barnes C, Ignjatovic V. et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost 2006; 95: 362-372.
• 10 Barry E, DeAngelo DJ, Neuberg D. et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol 2007; 25: 813-819.
• 11 Moghrabi A, Levy DE, Asselin B. et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95–01 for children with acute lymphoblastic leukemia. Blood 2007; 109: 896-904.
• 12 Veerman AJP, Hahlen K, Kamps WA. et al. High cure rate with moderate intensive treatment regimen in non-high risk childhood ALL. Results of protocol VI (1984–1988) from the Dutch Childhood Leukemia Study Group. J Clin Oncol 1996; 14: 911-918.
• 13 Clauss A. Gerinnungsphysiol. Schnellmethode zur Bestimmung des Fibrinogens. Acta Haemat 1957; 17: 237-246.
• 14 Ries M, Klinge J, Rauch R. Age-related reference values for activation markers of the coagulation and fibrinolytic system. Thromb Res 1997; 85: 341-344.
• 15 Flanders MM, Phansalkar AR, Crist RA. et al. Pediatric reference intervals for uncommon bleeding and thrombotic disorders. J Pediatr 2006; 149: 275-277.
• 16 Dykes AC, Walker ID, McMahon AD. et al. A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 2001; 113: 636-641.
• 17 Caruso V, Iacoviello L, Di Castelnuovo A. et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006; 108: 2216-2222.
• 18 Mall V, Thomas KB, Sauter S. et al. Effect of glucocorticosteroids, E. Coli- and Erwinia L-Asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia. Klin Padiatr 1999; 211: 205-210.
• 19 van Giezen JJ, Brakkee JG, Dreteler GH. et al. Dexamethasone affects platelet aggregation and fibrinolytic activity in rats at different doses which is reflected by their effect on arterial thrombosis. Blood Coagul Fibrinolysis 1994; 05: 249-255.
• 20 Patrassi GM, Sartori MT, Livi U. et al. Impairment of fibrinolytic potential in long-term steroid treatment after heart transplantation. Transplantation 1997; 64: 1610-1614.
• 21 Sevaljevic L, Macvanin M, Zakula Z. et al. Adrenalectomy and dexamethasone treatment alter the patterns of basal and acute phase response-induced expression of acute phase protein genes in rat liver. J Steroid Biochem Mol Biol 1998; 66: 347-353.
• 22 Uszynski M, Osinska M, Zekanowska E. et al. Children with acute lymphoblastic leukemia: is there any subgroup of children without elevated thrombin generation? A preliminary study utilizing measurements of thrombin-antithrombin III complexes. Med Sci Monit 2000; 06: 108-111.
• 23 Sutherland DE, Weitz IC, Liebman HA. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol 2003; 72: 43-52.
• 24 Giordano P, Del Vecchio GC, Santoro N. et al. Thrombin generation in children with acute lymphoblastic leukemia: effect of leukemia immunophenotypic subgroups. Pediatr Hematol Oncol 2000; 17: 667-672.
• 25 Monagle P, Chan AK, Albisetti M. et al. Fibrinolytic system in adolescents: response to venous occlusion stress tests. Pediatr Res 2003; 53: 333-337.
• 26 Bushman JE, Palmieri D, Whinna HC. et al. Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia. Leuk Res 2000; 24: 559-565.
• 27 Müller HJ, Boos J. Use of L-Asparaginase in childhood ALL. Crit Rev in Oncol/Heamat 1998; 28: 97-113.
• 28 Boos J, Werber G, Ahlke E. et al. Monitoring of Asparaginase Activity and Asparagine Levels in Children on Different Asparaginase Preparations. Eur J Cancer 1996; 32A: 1544-1550.
• 29 Appel IM, Hop WC, Pieters R. Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases. Blood Coagul Fibrinolysis 2006; 17: 139-146.
• 30 Nowak-Gottl U, Werber G, Ziemann D. et al. Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhoodALL. Haematologica 1996; 81: 127-131.
• 31 Nowak-Gottl U, Ahlke E, Schulze-Westhoff P. et al. Changes in coagulation and fibrinolysis in childhood ALL: a two-step dose reduction of one E. coli asparaginase preparation. Br J Haematol 1996; 95: 123-126.
• 32 Nowak-Gottl U, Kuhn N, Wolff JE. et al. Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase-treated children. Eur J Haematol 1996; 56: 35-38.
• 33 Mitchell L, Hoogendoorn H, Giles AR. et al. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency. Blood 1994; 83: 386-391.
• 34 Mauz-Korholz C, Junker R, Gobel U. et al. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols). Thromb Haemost 2000; 83: 840-843.
• 35 Nowak-Gottl U, Heinecke A, von Kries R. et al. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 2001; 103: 165-172.
• 36 Mitchell LG, Andrew M, Hanna K. et al. Aprospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 2003; 97: 508-516.
• 37 Weyrich AS, Denis MM, Schwertz H. et al. mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets. Blood 2007; 109: 1975-1983.
• 38 Iiboshi Y, Papst PJ, Kawasome H. et al. Amino Acid-dependent Control of p70 s6k. J Biol Chem 1999; 274: 1092-1099.